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Abstract
Asthma has been associated with a higher incidence of myocardial infarction (MI), higher prevalence of MI risk
factors andhigher burdenof cardiovascular diseases.However, detailed associations between thepresentation and
initial management at the time of MI and post-MI outcomes in people with asthma compared to the general
population have not been studied. A total of 300,161 people were identified with a first MI over the period
2003–2013 in the Myocardial Ischaemia National Audit Project database, of whom 8922 (3%) had asthma.
Logistic regression was used to compare presentation, in-hospital care, in-hospital and 180-day post-discharge
all-cause mortality in people with and without asthma adjusting for demographics and comorbidities, diagnosis on
arrival and secondary prevention. People with asthma were more likely to have a delay in their MI diagnosis
following an STEMI (ST-elevation myocardial infarction; odds ratio (OR) 1.38, confidence interval CI 1.06–1.79)
but not an nSTEMI (non-ST-elevation myocardial infarction; OR 1.04, CI 0.92–1.17) compared to people without
asthma and a delay in reperfusion (OR 1.19, CI 1.09–1.30) following an STEMI. They were much less likely to be
discharged on a beta blocker following an STEMI or nSTEMI (OR 0.24, CI 0.21–0.28 and OR 0.27, CI 0.24–0.30,
respectively). There was no difference in in-hospital or 180-day mortality (OR 0.98, CI 0.59–1.62 and OR 0.99, CI
0.72–1.36) following an STEMI or nSTEMI (OR 0.89, CI 0.47–1.68 and OR 1.05, CI 0.85–1.28). Although people
with asthma were more likely to have a delay in diagnosis following an STEMI but not an nSTEMI compared to the
general population, were more likely to have a delay in reperfusion therapy and were much less likely to receive
beta blockers following an STEMI or nSTEMI, there was no difference in the prescriptions of other secondary
preventionmedications. None of the differences in presentation or management were associated with an increase
in all-cause in-hospital or 180-day mortality in people with asthma compared to the general population.
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Introduction
Asthma is a chronic inflammatory disease of the air-
ways associated with local hyper-responsiveness and
infiltration of immune system cells.1, 2 Worldwide,
asthma is estimated to affect between 240 million and
315 million people, affecting adult women more than
men.3, 4 In England alone, asthma affects over 5.6 mil-
lion people, representing a challenge to both quality
of life and health services costs.5
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Coronary artery disease is a major cause of death
worldwide, and despite declining age-specific mortal-
ity rates in developed countries, a shift towards ageing
populations maintains growing absolute numbers.6 In
the United Kingdom, the incidence of myocardial
infarction (MI) in 2009 was estimated as 255
events/100,000 person-years for men and 113
events/100,000 person-years for women, being
responsible for over 18% of male and 13% of female
deaths.7
Previous studies have shown that the burden of
ischemic heart disease is higher in people with asthma
compared to the general population with increased
risk varying from 40% to 90%.8–11 This increased risk
is thought to be based on common pathological char-
acteristics including shared inflammatory pathways
between asthma and cardiovascular disease, susceptibil-
ity to atherosclerosis and cytokine upregulation.12–14
People with asthma also commonly have comorbid-
ities considered risk factors for MI, such as obesity,
depression, anxiety and chronic obstrcutive pulmon-
ary disease COPD.15–17 A cohort study investigating
comorbidities in people with asthma in the UK pri-
mary care estimated that they have 3.5 times the risk
of having any cardiac comorbidity diagnosed compared
to the general population.18 More recently, two cross-
sectional studies found a higher prevalence of angina,
hypertension, stroke and heart failure among people
with asthma, with associations overall stronger for the
elderly and for women.19, 20 Although less evidence
exists around mortality, previous studies have shown a
higher proportion of ischaemic and non-ischaemic
deaths among asthmatics compared to the general
population, with cardiovascular disease estimated as
a major cause of mortality among the elderly.21
Despite the increased risk of cardiovascular dis-
ease, no published study to date has investigated diag-
nosis and management of post-MI comparing people
with and without asthma. We have recently investi-
gated differences in presentation, diagnosis and man-
agement of MI in people with and without COPD.22
We found that people with COPD had higher mortal-
ity post-MI compared to the general population and
that this might be explained in part by differences in
recognition and management of MI. Therefore, we
hypothesised that the same may be true for people
with asthma. Using the Myocardial Ischaemia
National Audit Project database (MINAP),23 we
investigated the differences in presentation, manage-
ment and prognosis following a first MI in people
with and without asthma.
Methods
Data source
MINAP is a registry of all admissions for MI and
other acute coronary syndromes (ACSs) to hospitals
in the United Kingdom from 2003. The data set
includes information on patient demographics,
comorbidities, drugs on admission, initial diagnosis,
final diagnosis, in-hospital drug treatment, timing of
reperfusion therapies, in-hospital outcome and drugs
given on discharge.9
Study population
All patients with a first diagnosis of ST-elevation
myocardial infarction (STEMI) from January 2003
to June 2013 or non-ST-elevation myocardial infarc-
tion (nSTEMI) from January 2004 to December 2012
were included. Records were excluded where there
was not a unique patient identifier; if there were
missing values for presence of obstructive airway
disease (OAD) or smoking history; or if Office of
National Statistics (ONS) mortality data were miss-
ing (Figure 1).
Exposure definition
The exposure of interest was asthma. The MINAP
database does not collect asthma status directly but
the presence of self-reported OADs, which may be
either asthma or COPD, is recorded. To differentiate
patients with asthma and COPD, those with asthma
were defined as those with OAD who never smoked,
whereas COPD patients were considered ex-smokers
or current smokers. This approach was recently used
in a similar study investigating COPD patients in the
same data set and has been used in other studies.22, 23
The validity of this method in MINAP was ascer-
tained through a linkage of a subset of data between
MINAP and Clinical Practice Research Datalink
CPRD, a large UK clinical database of primary med-
ical care involving more than 5 million active
patients.24,25 In that strategy, COPD patients were
identified in MINAP with agreement of 90.9%.
Presentation
Features including age, sex, ethnicity, type of MI,
final diagnosis as STEMI or nSTEMI and comorbid-
ities associated with presentation at the time of admis-
sion to hospital were compared between people with
and without asthma.
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Recognition and management
Delay in diagnosis of MI, use and time to reperfusion
after an STEMI, admission to a coronary care unit
(CCU) use of angiography or percutaneous coronary
intervention PCI/coronary artery bypass graft CABG
in hospital after an nSTEMI and discharge on sec-
ondary prevention drugs were investigated in both
groups. Two definitions of delay in diagnosis were
investigated. For patients with a final diagnosis of
STEMI, this was delay in diagnosis of definite
STEMI (defined as those who did not have an initial
diagnosis of definite STEMI). For those patients
with a final diagnosis of nSTEMI, this was delay
in diagnosis of ACS (defined as those whose initial
diagnosis was not STEMI, probable MI or ACS).
Delay in reperfusion was defined as any fibrinolysis
done 30 minutes after diagnosis or any primary per-
cutaneous coronary intervention pPCI done 90 min-
utes after diagnosis.26
Mortality outcomes
We investigated in-hospital and 180-day post-
discharge all-cause mortality. In-hospital mortality is
compulsorily recorded in MINAP. The UK ONS col-
lects data on all recorded deaths in England and
Wales.27 MINAP is linked with ONS mortality data,
which provides data on vital status at 180 days post-
discharge. Mortality at 180 days post-discharge was
assessed for those who survived until discharge.
Statistical analyses
The baseline characteristics (demographics and
comorbidities) were tabulated for people with and
without asthma. Logistic regression was used to con-
trol for age and gender differences. The main analysis
was conducted separately for STEMIs and nSTEMIs.
The same approach was used for management and
mortality outcomes. First, people with and without
asthma were compared in each outcome using percen-
tages and percentage differences. Then, logistic
regression was used to calculate crude odds ratios
(ORs). Sequentially, we added age, sex, smoking sta-
tus and comorbidities to the models.
To decide which comorbidities would be
included in the full model, conceptual frameworks
were designed and variables determined a priori as
possible confounders were preselected, indepen-
dently of a statistical significant association with
exposure or outcome. The comorbidities: diabetes,
cerebrovascular disease, chronic kidney disease,
congestive cardiac failure, previous angina, hyper-
tension, treatment of hypercholesterolemia, treat-
ment with antiplatelet therapy, previous PCI or
previous CABG, tachycardia at admission and
hypotension at admission were selected based on
Figure 1. Patient selection flowchart.
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prediction scores for MI management and mortal-
ity.28–30 Obesity was not included as this variable
was poorly recorded.
Missing values
Missing valueswere not imputed for demographic char-
acteristics. Missing values for comorbidities collected
as categorical variables were imputed following the
suggested approach for MINAP, imputing unrecorded
as ‘no’ or ‘absent’. Comorbidities collected as quantita-
tive andanalysed as categorical variables using a thresh-
old (e.g. obesity) were not imputed, and only complete
case records were analysed. Discharge medications
were imputed as per the comorbidities. For the other
outcomes, only complete case records were analysed.
Sensitivity analysis
A sensitivity analysis was conducted restricting the
analysis to never smokers only to account for eventual
unaccounted confounding by smoking status.
Ethics
This study was approved by LSHTM MSc Research
Ethics Committee (9719) and the MINAP academic
group (13-MNP-07).
Results
Presentation
A total of 300,161 patients were identified with a first
MI over the study period (2003–2013), of whom 8922
(3%) had asthma. On presentation with an MI, people
with asthma were older than those without (mean age
72.8 vs. 67.3), were more likely to be female (54.4%
vs. 32.5%) and had a higher proportion of nSTEMIs
than STEMIs (65.5% vs. 53.9%, OR 1.29, 95%CI
1.23–1.35). By definition, all people with asthma were
never smokers compared to 27.1% of non-asthmatics.
After controlling for age, sex and smoking sta-
tus, people with asthma were more likely to have
had previous angina (OR 1.22, CI 1.16–1.29),
tachycardia at admission (OR 1.41, CI 1.33–1.49),
chronic kidney disease (OR 1.34, CI 1.22–1.49),
congestive cardiac failure (OR 1.81, CI 1.65–
1.99), diabetes (OR 1.12, CI 1.06–1.18) and per-
ipheral vascular disease (OR 1.18, CI 1.03–1.35).
They were less likely to have a family history of
MI (OR 0.93, CI 0.88–0.99) or hyperlipidaemia
(OR 0.92, CI 0.87–0.97; Table 1).
In-hospital management
A total of 137,066 patients were identified with an
STEMI, of whom 3076 (2.2%) were asthmatics.
After adjustment for age, sex, smoking status, calen-
dar year and comorbidities, people with asthma were
more likely to have a delay in their diagnosis (OR
1.38, CI 1.06–1.79), a delay in reperfusion (OR 1.19,
CI 1.09–1.30), however were not less likely to have
reperfusion therapy at all compared to those without
asthma (OR 0.93, CI 0.79–1.06). After adjusting for
potential confounders, those with asthma were less
likely to be admitted to a CCU following an nSTEMI
(OR 0.90, CI 0.85–0.96) but had the same odds of
admission to a CCU following an STEMI (OR 0.98,
CI 0.89–1.08). Median time to reperfusion following
admission for STEMI was 45.9 minutes interquartile
range (IQR, 30.6–74.3) for asthmatics and 43.7 min-
utes (IQR, 28.4–69.9) for non-asthmatics for those
who had pPCI; and 32.8 minutes (IQR, 19.7–74.3)
for asthmatics and 28.4 minutes (IQR, 17.5–56.8) for
non-asthmatics for those who had thrombolysis.
With respect to prescription of secondary preventa-
tive medications, people with asthma had 76% lower
odds of being discharged with beta blockers in
the fully adjusted model (OR 0.24, CI 0.21–0.28;
Table 2).
A total of 165,095 patients were identified with an
nSTEMI, of whom 5846 (3.6%) had a diagnosis of
asthma. After adjustment for age, gender, calendar
year and comorbidities, there was no evidence of a
delay in diagnosis (OR 1.04, CI 0.92–1.17) between
people with and without asthma but those with asthma
were less likely to have elective PCI/CABG (OR 0.88,
CI 0.82–0.95). With respect to secondary prevention,
people with asthma had 73% lower odds of being
discharged with beta blockers in the fully adjusted
model (OR 0.27, CI 0.24–0.30; Table 3). There was
no difference in the prescription of other secondary
prevention medications.
Mortality
There were 7165 in-hospital deaths following an
STEMI. After controlling for age, sex, smoking sta-
tus, calendar year and comorbidities, there was no
evidence of a difference in in-hospital mortality
between people with and without asthma (OR 0.98,
CI 0.59–1.62). This was also seen for 180-day post-
discharge all-cause mortality (OR 0.99, CI 0.72–1.36;
Table 4).
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There were 9775 in-hospital deaths following
an nSTEMI. There was no difference in in-
hospital mortality in people with and without
asthma after adjusting for confounders (OR
0.89, CI 0.47–1.68) or in 180-day post-discharge
all-cause mortality (OR 1.05, CI 0.85–1.28;
Table 5).
Sensitivity analysis
The analysis was repeated restricting the population
to non-smokers only. Minimal differences were seen
compared to the main analysis (see Tables S1 and S2
for full results of all analyses). In all, 35,775 patients
admitted with an STEMI were non-smokers, of whom
Table 1. Comparison on demographics and comorbidities between people with and without asthma.
Total patients 300,161 (100%)
No asthma
291,239 (97%)
Asthma 8922
(3%)
Baseline characteristics
OR adjusted for age, sex and smoking
(no asthma as baseline)
Age
35–50 38,273 (13.1%) 579 (6.5%)
51–60 58,603 (20.1%) 1018 (11.4%)
61–70 70,135 (24.1%) 1831 (20.5%)
71–80 69,644 (23.9%) 2826 (31.7%)
81 and older 54,421 (18.7%) 2261 (29.8%)
Mean age 67.3 72.8
Gender (n ¼ 299,125)
Male 195,648 (67.4%) 4053 (45.5%)
Female 94,579 (32.5%) 4845 (54.4%)
Ethnicity (n ¼ 167,261)
White 153,093 (94.3%) 4508 (89.2%)
Non-White 9114 (5.6%) 546 (10.8%)
Smoking status
Never 79,041 (27.1%) 8922 (100.0%)
Ex-smoker 107,277 (36.8%) 0
Current 104,291 (36.0%) 0
Type of MI
STEMI 133,990 (46.0%) 3076 (34.4%) 1 (reference)
nSTEMI 157,249 (53.9%) 5846 (65.5%) 1.29 (1.23–1.35)
Previous angina 46,975 (16.1%) 1886 (21.1%) 1.22 (1.16–1.29)
Previous PCI 7371 (2.5%) 236 (2.6%) 1.03 (0.90–1.18)
Previous CABG 6309 (2.1%) 187 (2.1%) 0.92 (0.79–1.07)
Diabetes (n ¼ 296,535) 43,737 (15.2%) 1658 (18.8%) 1.12 (1.06–1.18)
Familial history of MI
(n ¼ 218,072)
73,986 (34.9%) 1735 (27.5%) 0.93 (0.88–0.99)
Treated for Hypertension 128,756 (44.2%) 4,432 (39.6%) 0.96 (0.92–1.00)
Treated for hyperlipidaemia 80,479 (27.63%) 2262 (25.3%) 0.92 (0.87–0.97)
Treated with antiplatelets 65,116 (22.2%) 2195 (24.6%) 1.01 (0.96–1.07)
Peripheral vascular disease 10,776 (3.7%) 248 (2.8%) 1.18 (1.03–1.35)
Cerebrovascular disease 18,959 (6.5%) 688 (7.7%) 1.01 (0.93–1.10)
LVEF left ventricular ejection fraction<30% (n
¼ 99,198)
9499 (9.8%) 281 (10.2%) 0.98 (0.86–1.12)
Chronic kidney disease 9648 (3.3%) 464 (5.2%) 1.34 (1.22–1.49)
Congestive cardiac failure 8894 (3.0%) 573 (6.4%) 1.81 (1.65–1.99)
Hypotension at admission
(n ¼ 271,974) systolic blood pressure
SBP <90 mmHg
9161 (3.5%) 247 (3.0%) 0.85 (0.74–0.98)
Tachycardia at admission
(n ¼ 272,761) heart rate HR >100 BPM
77,522 (29.3%) 3140 (38.6%) 1.41 (1.33–1.49)
OR: odds ratio; STEMI: ST-elevation myocardial infarction; nSTEMI: non-ST-elevation myocardial infarction; MI: myocardial infarction.
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Table 3. In-hospital management for nSTEMIs.
No asthma (n, %)
157,249
Asthma (n, %)
5846
Total (n, %)
163,095
Crude OR
(95% CI)
Fullya adjusted OR
(95% CI)
In-hospital management for nSTEMIs
Diagnosis and admission
Diagnosis delay n ¼ 57,321 (36.5%) n ¼ 2595 (44.4%) 1.39 (1.32–1.46) 1.04 (0.92–1.17)
Admission to CCU n ¼ 162,343 n ¼ 59,506 (38.0%) n ¼ 1921 (33.0%) 0.80 (0.76–0.84) 0.90 (0.85–0.96)
Invasive procedures
Elective angiography n ¼ 80,193 (51.0%) n ¼ 2470 (42.3%) 0.70 (0.66–0.74) 0.83 (0.72–0.95)
Elective PCI/CABG n ¼ 37,729 (24.5%) n ¼ 1053 (18.0%) 0.69 (0.65–0.74) 0.88 (0.82–0.95)
Secondary prevention
Discharge on BB n ¼ 159,345 n ¼ 96,744 (61.5%) n ¼ 1968 (33.7%) 0.30 (0.28–0.32) 0.27 (0.24–0.30)
Discharge on antiplatelet 81.3% 82.4% 1.07 (1.00–1.15) 1.03 (0.96–1.11)
Discharge on aspirin
n ¼ 159,345
n ¼ 117,257 (76.3%) n ¼ 4262 (75.0%) 0.93 (0.87–0.98) 0.94 (0.82–1.08)
Discharge on clopidogrel
n ¼ 159,345
n ¼ 86,326 (56.2%) n ¼ 3084 (54.2%) 0.92 (0.87–0.97) 1.02 (0.9–1.16)
Discharge on statin n ¼ 159,345 n ¼ 115,549 (75.2%) n ¼ 4140 (72.7%) 0.91 (0.85–0.97) 0.96 (0.84–1.10)
Discharge on ACEi n ¼ 159,345 n ¼ 98,429 (64.1%) n ¼ 3521 (61.9%) 0.94 (0.88–0.99) 0.97 (0.85–1.09)
OR: odds ratio; nSTEMI: non-ST-elevation myocardial infarction; CCU:coronary care unit; MI: myocardial infarction.
aAdjusted for age, sex, smoking, year of admission, diabetes, CVSD, CRF, CCF, PVD, low LVEF, previous angina, previous PCI, previous
CABG, family history of MI, treatment for hypertension, treatment for hyperlipidaemia, treatment with antiplatelets, tachycardia and
hypotension at admission.
Table 2. In hospital management for STEMIs.
No asthma (n,%)
133,990
Asthma (n,%)
3076
Total (n,%)
137,066
Crude OR
(95% CI)
Fullya adjusted OR
(95% CI)
In-hospital management for STEMIs
Diagnosis and admission
Diagnosis delay n ¼ 8261 (6.2%) n ¼ 323 (10.5%) 1.45 (1.34–1.58) 1.38 (1.06–1.79)
Admission to CCU (n ¼ 135,927) n ¼ 112,594 (84.7%) n ¼ 2480 (81.3%) 0.79 (0.72–0.86) 0.98 (0.89–1.08)
Invasive procedures
Delayed reperfusion n ¼ 111,470 n ¼ 42,425 (38.9%) n ¼ 1047 (45.2%) 1.30 (1.19–1.41) 1.19 (1.09–1.30)
Use of reperfusion n ¼ 106,207 (79.3%) n ¼ 2231 (72.5%) 0.69 (0.64–0.74) 0.93 (0.79–1.10)
Use of pPCI n ¼ 47,382 (35.4%) n ¼ 931 (30.27%) 0.79 (0.73–0.86) 0.92 (0.8–1.06)
Secondary prevention
Discharge on beta blocker BB n ¼
132,588
n ¼ 99,175 (74.0%) n ¼ 1399 (45.5%) 0.27 (0.25–0.30) 0.24 (0.21–0.28)
Discharge on aspirin n ¼ 132,588 n ¼ 110,429 (85.2%) n ¼ 2418 (82.6%) 0.84 (0.80–0.88) 0.97 (0.78–1.21)
Discharge on clopidogrel
n ¼ 132,588
n ¼ 83,102 (64.1%) n ¼ 1785 (61.0%) 0.87 (0.83–0.90) 1.05 (0.87–1.27)
Discharge on statin n ¼ 132,588 n ¼ 110,382 (85.1%) n ¼ 2431 (83.1%) 0.93 (0.84–1.04) 1.17 (0.92–1.48)
Discharge on angiotensin converting
enzyme inhibitor ACEi n ¼ 132,588
n ¼ 103,602 (79.9%) n ¼ 2253 (77.0%) 0.89 (0.81–0.97) 1.10 (0.91–1.35)
OR: odds ratio; STEMI: ST-elevation myocardial infarction; CCU:coronary care unit; MI: myocardial infarction.
aAdjusted for age, sex, smoking, year of admission, diabetes, Cerebrovascular disease CVSD, chronic renal failure CRF, congestive
cardiac failure CCF, peripheral vascular disease PVD, low LVEF, previous angina, previous PCI, previous CABG, family history of MI,
treatment for hypertension, treatment for hyperlipidaemia, treatment with antiplatelets, tachycardia and hypotension at admission.
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3076 (8.6%) had asthma; 52,188 patients admitted
with an nSTEMI were non-smokers, of whom 5846
(10.5%) had asthma. There was no difference in in-
hospital or 180-day mortality following an STEMI or
nSTEMI in this analysis (Tables S1 and S2).
Discussion
This study investigated differences in presentation,
management and mortality following a first MI in
people with and without asthma. We found that on
admission to hospital following an MI, people with
asthma were more likely to be older, female, and
have a number of pre-existing cardiovascular comor-
bidities. Following an STEMI, they were more likely
to have a delay in their diagnosis and a delay in reper-
fusion; however, differences in the median time to
reperfusion were very small. Those with asthma were
not less likely to receive reperfusion therapy or have
PCI. They were less likely to receive a beta blocker on
discharge but there was no difference in the prescrip-
tion of other standard secondary prevention medica-
tions on discharge. Following an nSTEMI, people
with asthma did not have a delay in diagnosis com-
pared to people without asthma, nor was there any
difference in acute in-hospital management. Again
they were less likely to receive a beta blocker on
discharge but there was no difference in the prescrip-
tion of other standard secondary prevention medica-
tions on discharge. Unlike following an MI in people
Table 4. Mortality following STEMIs.
Asthma status for
STEMIs
No asthma (n)
133,990
Asthma (n)
3076
Total (n)
137,066
Mortalitya for
STEMIs
Crude OR
(95% CI)
OR adjusted for age, sex,
smoking and comorbiditiesa
(95% CI)
Fully adjusted
OR (95%CI)
In-hospital
mortality
n ¼ 4329 (3.2%) n ¼ 149 (4.8%) 1.64 (1.43–1.87) 0.98 (0.59–1.63) 0.98 (0.59–1.62)b
180-day post-
discharge
mortality
n ¼ 132,583
n ¼ 7609 (5.9%) n ¼ 282 (9.6%) 1.62 (1.39–1.89) 0.96 (0.71–1.31) 0.99 (0.72–1.36)c
STEMI: ST-elevation myocardial infarction; OR: odds ratio; MI: myocardial infarction.
aAdjusted for age, sex, smoking, year of admission, diabetes, CVSD, CRF, CCF, PVD, low LVEF, previous angina, previous PCI, previous
CABG, family history of MI, treatment for hypertension, treatment for hyperlipidaemia, treatment with antiplatelets, tachycardia and
hypotension at admission
bAdjusted for a, diagnosis delay and use of reperfusion.
cAdjusted for b, beta blocker, aspirin, clopidogrel, statin and ACEi at discharge.
Table 5. Mortality following nSTEMIs.
Asthma status for
nSTEMIs
No asthma (n)
157,249
Asthma (n)
5846
Total (n)
163,095
Mortality for
nSTEMIs
CRUDE
OR (95% CI)
OR adjusted for age,
sex, smoking and
comorbiditiesa
(95%CI)
Fully adjusted
OR (95%CI)
In-hospital mortality n ¼ 3597 (2.3%) n ¼ 153 (2.6%) 1.32 (1.20–1.46) 0.89 (0.48–1.68) 0.89 (0.47–1.68)b
180-day post-
discharge mortality
n ¼ 159,343
n ¼ 17,003 (11.1%) n ¼ 872 (15.3%) 1.44 (1.31–1.57) 1.10 (0.90–1.33) 1.05 (0.85–1.28)c
nSTEMI: non-ST-elevation myocardial infarction; OR: odds ratio; MI: myocardial infarction.
aAdjusted for age, sex, year of admission, aiabetes, CVSD, CRF, CCF, previous angina, treatment for hypertension, treatment for
hypercholesterolemia, treatment with antiplatelets, previous PCI, previous CABG, tachycardia and hypotension at admission.
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with COPD,22 these differences were not associated
with an increase in mortality among people with
asthma. Perhaps this is unsurprising as the asthma
group was at substantially higher risk in terms of age,
congestive cardiac failure, chronic kidney disease and
diabetes. These competing risks may be more impor-
tant in terms of prognosis than prescription of beta
blockers and delays in treatment.
The higher prevalence of females and comorbid
conditions such as chronic kidney disease, diabetes
and congestive cardiac failure among people with
asthma was expected, and these associations have
been described in other populations.31–36 This adds
validity to our asthma definition. The lower preva-
lence of a family history of MI and hyperlipidaemia,
both important risk factors for MI, supports the con-
cept that asthma itself may be an independent risk
factor for MI.8–10, 20
We also noted a higher prevalence of tachycar-
dia, at the time of MI in people with asthma com-
pared to those without. It is possible that the higher
heart rate among people with asthma may be a
consequence of the use of beta-2 agonists used in
the treatment of asthma, suggesting that patients
might mistake the episode for an asthma acute
attack. Equally, the delay in diagnosis of STEMI
may arise as healthcare professionals mistake
breathlessness for an acute exacerbation of asthma,
rather than considering a cardiovascular event. The
higher prevalence of nSTEMIs compared to STEMI
among people with asthma suggests an impact of
respiratory diseases in the pathophysiology of
ischemic events, and similar results have been
demonstrated for COPD.22
Another new finding refers to the influence a
delayed diagnosis of an STEMI had on delayed time
to reperfusion. Interestingly, though this delay in
perfusion was not associated with increased mortality,
something which was seen in a COPD population,22
and this likely represents the smaller median delay in
reperfusion for asthmatics compared to a larger delay
for those with COPD. Our study also highlights the
potential for patients with an established diagnosis to
be admitted to that speciality even when they present
with a different problem. This was evident for nSTE-
MIs but not STEMIs from our results. Following an
nSTEMI, those with asthma were less likely to be
admitted to CCU. This may be a reason why asthma
patients were less likely to receive investigations and
treatment such as angiography or PCI following
nSTEMI.
Our findings are in keeping with the previous lit-
erature; however, many previous studies have focused
collectively on OADs (asthma or COPD combined as
an exposure),37–39 with four having studied COPD
patients with a clinical or pharmacological exposure
definition, without spirometry or imaging to differ-
entiate between asthma and COPD.39–42 In six of
seven of these studies, patients with OADs were older
and more likely to be female, except Chen et al.42
Four studies split the analysis into STEMIs and nSTE-
MIs; and in all studies, nSTEMIs were more common
among people with OADs.37,38,41,43 Comorbidities
varied more among the studies. Overall, OAD
patients were more likely to be hypertensive,37,39,40,43
diabetic,37,38,41,43 have cardiac failure,39–41,43 previ-
ous angina38,39 and chronic kidney disease.39–41,43
They were also admitted with higher mean heart
rate38,41,43 and one reported lower mean systolic
blood pressure.43
In-hospital procedures have also been shown to be
different among people with and without OADs. In
six studies, patients with COPD or asthma were less
likely to undergo invasive procedures (pPCI, PCI,
CABG and angiography). Two studies investigated
delayed reperfusion, but this was not seen to differ
between those with and without OADs.38, 43 All stud-
ies reported lower prescription of in-hospital or beta
blockers at discharge. In-hospital mortality was inves-
tigated in four studies.38,39,41,43 In three studies, mor-
tality was higher in those with OAD but only in
nSTEMIs.39,40,43 Long-term mortality (1 year) was
investigated in three studies, and OADs were an inde-
pendent predictor of higher mortality in all.37,40,42
A strength of our study is that the analysis was
restricted to the patients without prior infarctions, a
common approach to avoid confounding effects of
factors related to previous events (e.g. secondary pre-
vention medications, severity and type of infarction,
ascertainment of diagnosis, date of the event, etc.).
Additionally, having validated a diagnosis of COPD
using linked MINAP and primary care data previ-
ously,44 we were able to identify a population of peo-
ple with asthma unlike in other studies, allowing
investigation in this group alone. However, our study
has a number of limitations. Firstly, we were limited
in our ability to make a diagnosis of asthma in the
MINAP database, and differential misclassification is
expected in variables associated with smoking
status; particularly demographics and comorbidities
(e.g. over-representation of older people among asth-
matics). However, sensitivity analyses restricted to
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non-smokers only were used to assess validity of the
results. Secondly, OAD is a self-reported parameter in
the MINAP database. It is known that self-reporting
of OAD is less sensitive and less specific than spiro-
metry tests, and it is possible this led to some non-
differential misclassification, but this would simply
lead to a dilution of the results to the null. Finally,
180-day post-discharge mortality is ascertained by
linkage of MINAP with ONS which does not include
cause of death, and we could not differentiate MI-
related mortality with extraneous causes. This may
underestimate the effect of asthma and long-term
mortality because of smoking-related deaths in the
exposed group.
Conclusion
Although people with asthma were more likely to
have a delay in their diagnosis following an STEMI
but not an nSTEMI compared to the general popula-
tion, were more likely to have a delay in reperfusion
therapy and were much less likely to receive beta
blockers following an STEMI or nSTEMI, there was
no difference in the prescriptions of other secondary
prevention medications. None of the differences in
presentation or management were associated with an
increase in mortality in people with asthma compared
to the general population, suggesting that the relative
underuse of beta blockers in people with asthma is
appropriate.
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